We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cholecystectomy Not Likely to Cause Gastric Cancer

By HospiMedica staff writers
Posted on 23 Jul 2007
A new study has found that cholecystectomy (surgical removal of the gallbladder) is in all probability not causally related to gastric cancer. More...


Researchers at the Karolinska Institutet (Stockholm, Sweden) evaluated the risk of gastric cancer within a cohort of 251,672 individuals in the Swedish national inpatient register, who had undergone cholecystectomy between 1970 and 1997. All incident cases of gastric cancer were identified through linkage to the Swedish cancer registry. Standardized incidence ratios (SIRs) were calculated for comparisons with cancer rates of the general population in Sweden.

The study found that the risk of distal gastric cancer was 41% higher the first year after cholecystectomy than in the general population, but this excess risk fell to 11% higher during the ensuing 10 years. Beyond 10 years, the excess risk of distal gastric cancer almost completely disappeared. The excess risk of distal gastric cancer was apparent only among men and only among patients with more extensive surgery (cholecystectomy with choledocholithotomy). Similarly, the risk of gastric cardia cancer was twice as high during the first year after cholecystectomy as in the general population, but this excess risk completely disappeared thereafter, and there was no difference in risk according to sex or extent of surgery. The study findings were published in the June 2007 edition of the American Journal of Gastroenterology.

"Assuming a long latency time between initiation of gastric carcinogenesis and clinical presentation of gastric cancer and a continuous exposure, we would, contrary to our finding, have anticipated a trend of increasing risk with longer follow-up,” said lead author Dr. Katja Fall and colleagues. "Also, even with a delayed onset of disease among women, we would have expected some excess risk among women in the oldest age category and/or with the longest follow-up.”


Related Links:
Karolinska Institutet

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.